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The Japanese Breast Cancer Society (JBCS) registry began data collection in 1975, and started a new web-based system with the cooperation of the non-profit organization, Japan Clinical Research Support Unit and the Public Health Research Foundation (Tokyo, Japan) in 2004. The registry, starting in 2012, runs on the National Clinical Database (NCD) which is a multidisciplinary registry platform for interventional and cancer registries. The details were described previously \[[@CR1]\]. The eligibility for registration is that patients were diagnosed to have a new onset breast cancer at NCD participating facilities throughout Japan. The registration criteria do not require the patient to have undergone a breast surgery. As NCD does not support the linkage of a patient across hospitals, double registration may occur especially for the cases without breast surgery. However, as 97.4% of patients registered in 2016 had breast surgery, there are few cases with double registration. As of 2016, it contains records of 656,896 breast cancer patients from more than 1400 hospitals throughout Japan. Affiliated institutions provide data covering more than 50 demographic and clinicopathologic characteristics of newly diagnosed primary breast cancer patients via a web-based registration system. Follow-up information on 5-, 10-, and 15-year prognosis after the first treatment (preoperative systemic therapy or surgery) is requested. The JBCS registry is directed and governed by the Registration Committee of JBCS. TNM classification is now registered according to the 7th edition of the Union for International Cancer Control staging system \[[@CR2]\], and histological classification is registered according to the General Rules for Clinical and Pathological Recording of Breast Cancer \[[@CR3]\], which was further transferred to the Classification of Tumors of the Breast and Female Genital Organs \[[@CR4]\].

Herein, we present the summary of the annual data of JBCS registry collected in 2016 (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}; Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}). The number of institutes involved in the 2016 registration was 1422, and the total number of patients was 95,870, including 5803 patients with simultaneous bilateral breast cancers. The incidence per year of breast cancer, including ductal carcinoma in situ, was reported to be 107,627 in 2016 by the National Cancer Center and the Ministry of Health, Labor and Welfare \[[@CR5], [@CR6]\]. Thus, approximately 84% of newly diagnosed breast cancer patients were included in the JBCS registry in 2016. While the number of patients has increased, the number of institutes has not increased since NCD was started in 2012 (Fig. [1](#Fig1){ref-type="fig"}). As a result, the number of registered patients per institute has gradually increased.Table 1Patients\' characteristicsAll*N* = 95,870%Gender Female95,25799.4 Male6130.6Female*N* = 95,257%Unilateral85,97390.3Bilateral Synchronous58036.1 Metachronous34793.7Family history Absent75,07378.8 Present13,19713.9 Unknown69857.3Menstruation Premenopausal31,25532.8 Postmenopausal61,25264.3 Unknown27482.9Surgery Present91,54196.1 Absent6620.7 Biopsy alone30543.2Tumor size Tis13,06913.7 T04440.5 T144,90547.1 T227,63629.0 T329333.1 T446094.8 Unknown16611.7Nodal status N077,03580.9 N112,70013.3 N220092.1 N317351.8 Unknown17781.9Metastasis M091,36295.9 M119572.1 Unknown19382.0Stage 012,98613.6 I41,49043.6 IIA22,13423.2 IIB76558.0 IIIA22002.3 IIIB30983.3 IIIC12291.3 IV19572.1 Unknown25082.6TNM classifications were identified using the UICC staging systemThe TNM classifications in this Table are from clinical dataTable 2Comparison of clinical and pathological classificationspTispT1pT2pT3Unknown*n*%*n*%*n*%*n*%*n*%*n*%(a) Tumor size cTis12,61816.4496339.3380530.2135610.75114.0198315.7 cT03830.56617.214838.63910.241.012632.9 cT140,44652.612763.232,17879.6418110.34531.123585.8 cT220,00726.02671.3505025.212,58362.98984.512096.0 cT314941.9181.21117.447431.777051.51218.1 cT415632.070.417911.579951.142126.915710.0 Unknown3540.5195.49125.74412.4339.316747.2 Total76,865100.066168.641,56254.119,47625.330904.061218.0NodeClinicalPathological*n*%N+ *n*%(b) Nodal status Negative68,87289.6052,12675.71--3723510.54--98421.210≤ 2730.4Unknown839612.2 Positive773010.1082210.61--3384949.84--9146719.010≤ 91511.8Unknown6778.8 Unknown2630.3Unknown263Total76,865100.0Total76,865The TNM classification was identified by the UICC staging system*N+* number of involved nodesTable 3Differences of biological features distinguishing distant metastasis (M0 and M1)M0M1*N* = 91,362%*N* = 1957%ER Negative12,96714.242421.7 Positive1--9%28983.2723.8 ≥ 10%65,92272.1119361.0 NE65457.21467.5 Unknown30303.31226.2PgR Negative21,20223.270436.0 Positive1--9%67447.41859.5 ≥ 10%53,57758.679840.8 NE67697.41487.6 Unknown30703.41221.7HER2 Negative62,10168.0118560.5 Positive10,67411.738619.7 NE12,06013.220110.3 Unknown65277.11859.5 HER2/IHC  026,98429.553327.2  1+27,33429.948524.8  2+Equivocal12,89214.129915.3   2+/ISHPositive195715.26923.1Negative778360.416755.8NE283121.96020.1Unknown3212.531.0 3+87179.531716.2 NE12,06013.220110.3 Unknown33753.71226.2M0M1*N* = 88,819%*N* = 1957%Nuclear grade 132,69936.823818.6 225,44528.633426.2 315,51417.537129.1 NE78148.81159.0 Unknown73478.321917.1*ER* estrogen receptor, *PgR* progesterone receptor, *HER2* human epidermal growth factor receptor 2, *IHC* immunohistochemistry, *ISH* in situ hybridization, *NE* not examinedThe TNM classification was identified by the UICC staging systemFig. 1Changes in the number of patients and institutes over timeFig. 2Frequencies of the patients with a family history based on patient interviewsFig. 3Menopausal statusFig. 4Distribution of onset ageFig. 5Body mass index (BMI) according to ageFig. 6Nodal status based on tumor size and subtypeFig. 7Proportion based on ER, PgR, and HER2 status
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Among the 95,870 patients, 95,257 were women (99.4%) and the mean ± standard deviation of onset age was 59.7 ± 13.9 years. We show data of patient characteristics on female breast cancer, such as unilateral or bilateral disease, family history, menstruation, operation, tumor size, nodal status, metastasis, and stage in Table [1](#Tab1){ref-type="table"}. There were 13,197 (13.9%) patients with a family history of breast cancer. Family history in NCD means that at least one first- or second-degree relative have a history of breast cancer. Patients with family history of breast cancer based on patient interviews have increased since 2013, perhaps reflecting our growing interest in the family history of hereditary tumors around that time (Fig. [2](#Fig2){ref-type="fig"}). This is also supported by the decreasing proportion of those with "unknown" family history status. According to the meta-analysis in United Kingdom, it was reported that at least one first-degree relative had a history of breast cancer in 12.9% of breast cancer patients \[[@CR7]\], which is similar to the proportion in this report, but the true reason of the increased proportion of patients with a family history of breast cancer is unclear in this study.

Moreover, we found that 33% of breast cancer patients were premenopausal (Table [1](#Tab1){ref-type="table"}), which is closely related to the distribution of onset age. To view this from another angle, we analyzed data on menstruation by age. As a result, approximately half of Japanese breast cancer patients at age 52 were premenopausal (Fig. [3](#Fig3){ref-type="fig"}). The data may aid the clinicians to decide whether to begin aromatase inhibitors for menopausal patients who are not menstruating after chemotherapy or tamoxifen. The distribution of breast cancer patients by age of onset is shown in Fig. [4](#Fig4){ref-type="fig"}. The bimodal distribution of onset in late 40 s and late 60 s is unique in Japanese patients and there has been a similar trend for years. We also analyzed the data on body mass index by age. As shown in Fig. [5](#Fig5){ref-type="fig"}, the body mass index of Japanese patients steadily increases after their late 40 s. Proper control of their own body weight is recommended, because obesity is known as one of risk factors for postmenopausal breast cancer.

Our data show the comparison of clinical and pathological classifications on tumor size and nodal status in 76,865 patients without preoperative systemic therapy and M1 disease (Table [2](#Tab2){ref-type="table"}). Pathological T1 classification was similar in the number relative to that in clinical T1 classifications, while only 39.3% of the clinical Tis cases were diagnosed as Tis pathologically (Table [2](#Tab2){ref-type="table"}a), suggesting clinical Tis may be overestimated. Thus, our data revealed that there were not a few differences between clinical and pathological Tis evaluations. Furthermore, of 68,872 clinical node-negative cases, 52,126 (75.5%) was node negative but 12.1% was node-positive pathologically, while of 7730 clinical node-positive cases, 6231 (80.6%) was node positive but 10.6% was node-negative pathologically (Table [2](#Tab2){ref-type="table"}b). From this result, it is necessary to pay close attention to the selection of the surgical procedure.

The frequencies of lymph node metastasis by pathological tumor size and subtype in patients without neoadjuvant chemotherapy (NAC) are shown in Fig. [6](#Fig6){ref-type="fig"}. HER2-positive and triple negative breast cancer had high rates of lymph node metastasis compared to ER+ /HER2-- disease. For example, approximately 15% of pT1c disease had lymph node metastasis, while more than 30% of T2 cases had positive lymph nodes. Treatment should be selected based on such essential information as it when considering NAC or surgery.

Finally, our data show the frequency of subtypes classified based on ER, PgR, and HER2 expression from immunohistochemical staining, which is fundamental data of the population of Japanese breast cancer patients (Fig. [7](#Fig7){ref-type="fig"}). There were differences in these biological characteristics between M0 and M1 disease. In M1 cases, there was increased ER negativity, PgR negativity, HER2 positivity, and nuclear grade 3 (Table [3](#Tab3){ref-type="table"}). These factors should be considered first when evaluating biological features of individual breast cancer.
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The data input to JBCS registry has varied over time. This registry also needs to be gradually taking in the opinions of clinicians and balancing it with what has not changed. At the same time when we register new cases, we need to analyze, discuss, publish, and progressively develop JBCS registry. We believe that this annual data report provides significant information to guide daily medical care for breast cancer patients.
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